Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
2.740
-0.060 (-2.14%)
At close: Apr 28, 2026, 4:00 PM EDT
2.740
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:03 PM EDT
Company Description
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Jerome Durso |
Contact Details
Address: 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 United States | |
| Phone | 240 654 1450 |
| Website | altimmune.com |
Stock Details
| Ticker Symbol | ALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326190 |
| CUSIP Number | 02155H200 |
| ISIN Number | US02155H2004 |
| Employer ID | 20-2726770 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jerome Benedict Durso | Chairman, Chief Executive Officer and President |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer |
| Andrew Shutterly M.S. | Principal Financial and Accounting Officer and Corporate Controller |
| Bertrand Georges Ph.D. | Chief Technology Officer |
| Tony Blandin B.S. | Vice President of Quality and Compliance Management |
| Robin E. Abrams J.D. | Chief Legal Officer and Corporate Secretary |
| Linda M. Richardson | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | 8-K | Current Report |
| Apr 24, 2026 | 424B5 | Filing |
| Apr 22, 2026 | S-3MEF | Filing |
| Apr 22, 2026 | 424B5 | Filing |
| Apr 16, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 17, 2026 | ARS | Filing |
| Mar 17, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 6, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 6, 2026 | 10-K | Annual Report |